OptimizeRx (OPRX) Receivables (2010 - 2026)

OptimizeRx has disclosed Receivables across 17 years of filings, most recently posting $28.7 million for Q2 2026.

• In Q2 2026, Receivables fell 22.38% year-over-year to $28.7 million; the TTM figure through Jun 2026 stood at $28.7 million (down 22.38% YoY), while the FY2025 annual figure was $41.7 million, up 0.58% from the prior year.
• Receivables came in at $28.7 million for Q2 2026 at OptimizeRx, down from $36.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $42.3 million in Q4 2023 to a low of $17.8 million in Q3 2022.
• Average Receivables over 5 years is $29.2 million, with a median of $29.2 million recorded in 2024.
• Year-over-year, Receivables soared 64.46% in 2023 and decreased 22.38% in 2026.
• Over 5 years, Receivables stood at $25.7 million in 2022, then soared by 64.46% to $42.3 million in 2023, then fell by 2.07% to $41.5 million in 2024, then climbed by 0.58% to $41.7 million in 2025, then tumbled by 31.13% to $28.7 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $28.7 million in Q2 2026, $36.7 million in Q1 2026, and $41.7 million in Q4 2025.